UPDATE: Citi Raises BioMarin Pharmaceuticals' PT

According to a research report published this morning, Citi has increased BioMarin Pharmaceuticals' BMRN PT from $45 to $49. In the report, Citi said, "We hosted a lunch meeting with mgt that addresses several bear arguments. Overall, the key takeaways are: (1) the long-term tax rate will be lower than expected, (2) GALNS ph 3 should be successful, (3) mgt is talking up BMN-701 and PEG-PAL (both are upside to our TP), and (4) there will be more visibility on BMN-673 (PARP inh for ovarian cancer) in Q4:12. While many investors have been worried about mgt's body language re: GALNS and BMN-701, they seem very upbeat to us. We are raising our TP to $49 (+$4) due to a lower tax rate as their IP is domiciled abroad." Citi maintains its Buy rating on BioMarin Pharmaceuticals, which closed Friday at $38.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsCiti
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!